$86 Million

Kezar Life Sciences

Initial Public Offering

Bookrunner, June 2018

Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics to treat unmet needs in autoimmunity and cancer.